Identifying sources of potential harm to patients is UMC’s highest priority. Detecting and communicating signals of such harm lies at the heart of pharmacovigilance.
Signal detection aims to identify and describe suspected harm to patients, caused by their use of medicines. The evidence comes primarily in the form of spontaneous reports from health professionals across the world, from pharmaceutical companies and some from patients. Signal detection is a core UMC activity.
With the unique resource of VigiBase, signal detection is a top priority for UMC's multidisciplinary team.
Issues relating to the tentative nature of data underlying signals and to data protection matters
Meet the experts who support the UMC's signal detection process